Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs
Notice NOT-DA-23-002 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 30, 2021 Category: Research Source Type: funding
Notice of Change to Key Dates for PAR-19-261, "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)"
Notice NOT-HD-21-054 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2021 Category: Research Source Type: funding
Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
Funding Opportunity PAR-22-031 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-147 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacok...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2021 Category: Research Source Type: funding
Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
Funding Opportunity PAR-22-032 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-146 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacok...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2021 Category: Research Source Type: funding
ECosystem for Leading Innovation in Plasma Science and Engineering (ECLIPSE)
Full Proposal Deadline Date: November 15, 2021 Proposal deadline specified above for: PHY - Plasma Physics Program Guidelines: PD 21-110ZPlasma science is a transdisciplinary field of research where fundamental studies in many disciplines, including plasma physics, plasma chemistry, materials science, and space science, come together to advance knowledge for discovery and technological innovation. The primary goal of the ECosystem for Leading Innovation in (Source: NSF Upcoming Due Dates)
Source: NSF Upcoming Due Dates - October 16, 2021 Category: Science Source Type: funding
Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-048 from the NIH Guide for Grants and Contracts. There is consensus that environmental toxicants are a risk factor for AD/ADRD, but causality has been largely elusive. While human studies demonstrating an association of AD/ADRD with toxicant exposures are relatively abundant, there is a clear unmet need for more mechanistic research to support or refute the clinical relevance and the biological plausibility of an impact on disease initiation, progression, or modification. This is especially important for understanding the potentially modifiable causes of racial and socioeconomic inequities. Th...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2021 Category: Research Source Type: funding
Notice of Early Expiration of PAR-20-316 "NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)"
Notice NOT-NS-22-029 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 29, 2021 Category: Research Source Type: funding
NSF-DFG Lead Agency Activity in Chemistry and Transport in Confined Spaces (NSF-DFG Confine)
Available Formats: HTML: https://www.nsf.gov/pubs/2021/nsf21626/nsf21626.htm?WT.mc_id=USNSF_25&WT.mc_ev=clickPDF: https://www.nsf.gov/pubs/2021/nsf21626/nsf21626.pdf?WT.mc_id=USNSF_25&WT.mc_ev=clickDocument Number: nsf21626Public Comment: This is an NSF Program Announcements and Information item. (Source: NSF Program Announcements and Information)
Source: NSF Program Announcements and Information - September 22, 2021 Category: Science Source Type: funding
Partnerships for Research and Education in Chemistry (PREC)
Available Formats: HTML: https://www.nsf.gov/pubs/2021/nsf21620/nsf21620.htm?WT.mc_id=USNSF_25&WT.mc_ev=clickPDF: https://www.nsf.gov/pubs/2021/nsf21620/nsf21620.pdf?WT.mc_id=USNSF_25&WT.mc_ev=clickDocument Number: nsf21620Public Comment: This is an NSF Program Announcements and Information item. (Source: NSF Program Announcements and Information)
Source: NSF Program Announcements and Information - September 15, 2021 Category: Science Source Type: funding
Computational and Data-Enabled Science and Engineering (CDS & E)
Full Proposal Window: September 15, 2021 Division of Chemical, Bioengineering, Environmental, and Transport Systems Program Guidelines: PD 21-8084Large-scale simulations and the ability to accumulate massive amounts of data have revolutionized science and engineering. The goal of the CDS&E meta-program is to identify and capitalize on opportunities for major scientific and engineering breakthroughs through new computational and data-analysis approaches and best practices. The CDS&E meta-program supports projects that harness computation and data to advance knowledge and accelerate discovery above and beyond the goa...
Source: NSF Upcoming Due Dates - August 16, 2021 Category: Science Source Type: funding
Notice of Change to Add Responsiveness Criteria and Further Clarify Clinical Trials Allowed in PAR-20-316 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)"
Notice NOT-NS-21-076 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 4, 2021 Category: Research Source Type: funding
Notice of Change to Add Responsiveness Criteria and Further Clarify Clinical Trials Allowed in PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)"
Notice NOT-NS-21-078 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 4, 2021 Category: Research Source Type: funding
Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-274 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the program "Cancer Target Discovery and Development (CTD2, pronounced cee-tee-dee-squared). CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis. The primary purpose of CTD2 is to advance the following areas: Improving the under...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 12, 2021 Category: Research Source Type: funding
Environmental Convergence Opportunities in Chemical, Bioengineering, Environmental, and Transport Systems (ECO-CBET)
Available Formats: HTML: https://www.nsf.gov/pubs/2021/nsf21596/nsf21596.htm?WT.mc_id=USNSF_25&WT.mc_ev=clickPDF: https://www.nsf.gov/pubs/2021/nsf21596/nsf21596.pdf?WT.mc_id=USNSF_25&WT.mc_ev=clickDocument Number: nsf21596Public Comment: This is an NSF Program Announcements and Information item. (Source: NSF Program Announcements and Information)
Source: NSF Program Announcements and Information - July 6, 2021 Category: Science Source Type: funding
CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-21-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the eyes and lungs. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP). (...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 25, 2021 Category: Research Source Type: funding
